Dry powder inhalation of antibiotics in cystic fibrosis therapy, part 1: Development of a powder formulation with colistin sulfate for a special test inhaler with an air classifier as de-agglomeration principle

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 54, Issue 1, 2002, Pages 17-24

  De Boer, A H ^a   Le Brun, P P H ^b   Van der Woude, H G ^a   Hagedoorn, P ^a   Heijerman, H G M ^c   Frijlink, H W ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Central Hospital Pharmacy   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

Author keywords

Colistin sulfate; Cystic fibrosis; Inhalation; Laser diffraction analysis; Powder formulation; Test inhaler

Indexed keywords

COLISTIN; LACTOSE; ANTIINFECTIVE AGENT;

AEROSOL; ARTICLE; CYSTIC FIBROSIS; DRUG FORMULATION; DRY POWDER; FLOW RATE; LASER DIFFRACTION; PARTICLE SIZE; POWDER INHALER; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; POWDER; STATISTICS;

ADMINISTRATION, INHALATION; ANTIBIOTICS; CHEMISTRY, PHARMACEUTICAL; COLISTIN; CYSTIC FIBROSIS; NEBULIZERS AND VAPORIZERS; POWDERS; ANTI-BACTERIAL AGENTS;

EID: 0035985874     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(02)00043-7     Document Type: Article

References (33)

1. A review of the technical aspects of drug nebulization
2. The cleaning and disinfection of nebulizers used at home and in cystic fibrosis
3. Prevention of respiratory infections: Evaluation of contamination of two types of aerosol equipments
4. The science of nebulized drug delivery
5. Inhalation of tobramycin in cystic fibrosis. Part 1: The choice of a nebulizer
6. Halolite® a novel liquid drug aerosol delivery system
7. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis
8. Can tobramycin inhalation be improved with a jet nebulizer; A pharmacokinetic analysis
9. Inhaled micronized gentamicin powder: A new delivery system
10. Comparative evaluation of preliminary in vitro deposition results for tobramycin from WISTO Senior® nebulizer and two different dry powder inhalers
11. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis
12. Inspiratory flow rate and dynamic lung function in cystic fibrosis and chronic obstructive lung disease
13. Assessment of the ability of young children to use a powder inhaler device (Turbuhaler)
14. Charakteristika der inspiratorischen Fluss-Volumen-Kurven bei Kindern mit Asthma bronchiale and Patienten mit zystischer Fibrose
15. Drug delivery to the respiratory tract using dry powder inhalers
16. Aerosols for inhalation therapy
17. Some future perspectives for unit dose inhalation aerosols
18. Dry powder aerosols I: A new powder inhalation device
19. The relationship between physical properties of lactose monohydrate and the aerodynamic behavior of adhered drug particles
20. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate
21. Characterization of small changes in the physical properties of powder of significance for dry powder inhaler formulations
22. Turbuhaler: A new powder inhaler for administration of drugs to the airways
23. Local side-effects during 4-year treatment with inhaled corticosteroid - a comparison between pressurized metered-dose inhalers and Turbuhaler
24. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer®
25. The use of laser diffraction technique for the characterization of the aerosol cloud from inhalation devices
26. Protein measurement with the folin phenol reagent